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Amyotrophic lateral sclerosis (ALS) is considered a multifactorial, multisystem disease in which inflammation and the immune
system play important roles in development and progression. The pleiotropic cytokine TNFα is one of the major players
governing the inflammation in the central nervous system and peripheral districts such as the neuromuscular and immune
system. Changes in TNFα levels are reported in blood, cerebrospinal fluid, and nerve tissues of ALS patients and animal models.
However, whether they play a detrimental or protective role on the disease progression is still not clear. Our group and others
have recently reported opposite involvements of TNFR1 and TNFR2 in motor neuron death. TNFR2 mediates TNFα toxic
effects on these neurons presumably through the activation of MAP kinase-related pathways. On the other hand, TNFR2
regulates the function and proliferation of regulatory T cells (Treg) whose expression is inversely correlated with the disease
progression rate in ALS patients. In addition, TNFα is considered a procachectic factor with a direct catabolic effect on skeletal
muscles, causing wasting. We review and discuss the role of TNFα in ALS in the light of its multisystem nature.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal
adult motor neuron disease (MND), known since 1864, but
still mysterious as concerns the mechanism of onset and the
ineluctable progression characterized by increasing muscular
atrophy, with loss of strength, paralysis, and death [1–3].
Death is due to respiratory failure and occurs typically 3–5
years after diagnosis, although in some cases, survival is longer
than two decades [4]. Usually, the disease starts focally with
subtle weakness of the limb or bulbar muscles and then
spreads, progressing to paralysis of almost all skeletalmuscles.
The pathology encompasses distant biological systems includ-
ing the brain, spinal cord, and muscle/neuromuscular junc-
tions. It is now becoming clear that ALS also involves other
nonneuromuscular systems which may have substantial roles
in driving the degenerative process and/or influencing the rate
of disease progression, hence the prognosis. These systems
include the peripheral immune system, innate and adaptive,
and are influenced by the overall metabolic status [5, 6].
Nearly 90% of all ALS cases arise spontaneously, while
the remaining 10% are linked to genetic mutations, mostly
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inherited as a dominant trait. Along with the well-known
mutations in the Cu2+/Zn2+ superoxide dismutase (SOD1)
gene [7], discovered more than two decades ago as a unique
gene mutation specifically linked to ALS, twelve other ALS
genes have been discovered in the last ten years. These genes
can be grouped into several categories based on their protein
function and their involvement in (i) protein homeostasis,
such as optineurin [8], valosin-containing protein [9],
ubiquilin 2 [10], and TBK1 [11]; (ii) RNA metabolism and
function such as TAR DNA-binding protein 43 (TDP-43),
fused in sarcoma/translocated in liposarcoma (FUS/TLS)
[12], C9orf72 [13, 14], matrin 3 [15], and angiogenin [16]);
(iii) cytoskeletal dynamics of motor axons such as dynactin
subunit 1 [17], profilin 1 [18], and tubulin alpha-4 A chain
[19]; (iv) mitochondrial function such as CHCHD10 [20];
and (v) regulation of inflammation such as TBK1 [11]. This
genetic variability explains the complexity of the disease in
which heterogeneous mechanisms converge towards a com-
mon pathogenesis. These mechanisms include alterations in
RNA processing and stability, dysfunction in proteostasis
and protein quality control, mitochondrial dysfunction and
increased oxidative stress, defects of the cytoskeletal dynamics
in themotor axons and distal terminals, synaptic impairment,
and neuroinflammation [21].
Neuroinflammation is a typical hallmark of ALS, detect-
able in the nervous system and peripheral biological fluids.
While the disease progression in ALS is a result of slow and
progressive dysfunction and loss of motor neurons, other
nonneuronal cells in the central nervous system (CNS) and
peripheral nervous system (PNS), including the immune
cells, play crucial roles [22, 23]. Microglia and astroglia
proliferation and activation are prominent histological fea-
tures in the spinal cord and motor cortex of ALS patients
and have been detected in vivo by positron emission tomogra-
phy during the course of the disease [24, 25]. Infiltrates of
macrophages and T lymphocytes have been reported in both
the CNS and PNS of ALS patients and in animalmodels, testi-
fying the direct involvement of the immune system [6, 26–28].
TNFα is one of the major proinflammatory cytokines,
with a central role in the initiation and orchestration of
immunity and inflammation. TNFα participates in local
and systemic inflammation with pleiotropic actions includ-
ing both pro- and anti-inflammatory functions. It acts
through two main receptors, the p55 TNFα receptor
(TNFR1) and the p75 TNFα receptor (TNFR2), that differ
in their binding affinity for TNFα, expression pattern, and
downstream signal transduction cascades [29]. This cytokine
has been implicated in motor neuron death occurring in ALS
patients and animal models [30–33]. However, the contro-
versial results regarding its role in governing the progression
of the disease in ALS mice [34, 35] and the lack of efficacy of
the treatment with anti-TNFα therapeutics in patients [36]
have reduced the general interest about its possible relevance
in the pathology. Nevertheless, a recent gene expression
study using next-generation RNA sequencing (RNAseq,
Illumina) analysis in postmortem cervical spinal cord from
sporadic ALS patients identified significant elevation of
inflammatory processes with TNFα as a major regulatory
molecule [37]. TNFα was also detected as one of the main
candidate hubs in a gene coexpression network in the fibro-
blasts of ALS patients with C9orf72 mutation, underlying
its potential contribution to the altered immune response in
ALS [38]. There is also fresh evidence that the two receptors
TNFR1 and TNFR2 may act in opposite directions in motor
neuron degeneration, suggesting new perspectives in identi-
fying specific potential therapeutic targets [39, 40].
These recent discoveries, together with the increasing
evidence of the role of the immune system as a primary event
in ALS pathology, prompted us to re-examine the evidence
linking TNFα with the etiology of the disease. This review
discusses the potential role of TNFα at the intersection of
various cellular and molecular mechanisms associated with
the pathological alterations in ALS, not only in the nervous
system but also in relation to the muscle wasting and meta-
bolic changes that characterize the disease.
2. TNFα, TNFα Receptors, and Related
Intracellular Pathways in ALS
TNFα is a 26 kDa cytokine expressed by activated mono-
cytes/macrophages, microglia, and activated natural killer
and T cells and also by nonimmune cells like astrocytes,
endothelial cells, fibroblasts, and neurons [41]. Once synthe-
sized as a 233-amino acid-long type II transmembrane
monomeric protein, it is transferred into the membrane,
forming a stable homotrimer. Membrane-bound TNFα
(mTNFα) is then cleaved by TNFα-converting enzyme
(TACE), also called ADAM17, which releases a soluble form
of TNFα (sTNFα). This circulates throughout the body
displaying its potent endocrine function and its ability to
act at distant physiological sites.
Both soluble and membrane TNFα are biologically active,
and a number of factors, including cell status and stimuli,
control the balance between the two forms. Their signal
transduction involves binding with two transmembrane
receptors (TNFRs), TNFR1 and TNFR2, which are differ-
ently expressed and regulated and control different signaling
pathways. While TNFR1 is constitutively expressed in almost
all cells, TNFR2 is mainly expressed in lymphocytes and
other immune cells and is induced by different cell stimula-
tions [41]. TNFR1 binds to both sTNFα and mTNFα while
TNFR2 preferentially interacts with mTNFα and is believed
to play an important role in localized signaling during cell-
to-cell interactions, possibly also through “reverse signaling”
processes [41, 42]. The cytoplasmic tail of TNFR1 contains a
death domain that is missing in TNFR2.
Although initially TNFR1 activation was considered to be
primarily involved in the cytotoxic and apoptotic effects of
TNFα, while TNFR2 stimulation was related exclusively to
cell survival and proliferation, now, it is becoming clear that
TNFR2 can also induce cell death, directly or indirectly. For
instance, through a cell-to-cell interaction, the binding
between mTNFα and TNFR2 can induce tumor and neuro-
nal cell death [39, 43, 44].
The complex and divergent roles of TNFα-induced
TNFR signaling in apoptosis and inflammation have been
described elsewhere [45]. Of particular interest in the present
review is the role of TNFRs in modulation of the signaling
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mediated by the mitogen-activated protein kinase (MAPK)
cascade, implicated in neuroinflammatory and neurodegen-
erative mechanisms [45]. Moreover, membrane-integrated
TNFα can receive stimulation from TNFR binding, resulting
in a “reverse signaling”, that activates signals into the
mTNFα-bearing cell. This process enables a two-way com-
munication in cell-to-cell contact, possibly contributing to
the plasticity of the ligand-receptor systems and facilitating
the fine-tuning of the immune response [41, 46]. As dis-
cussed later, this mechanism can also play a significant role
in the interaction between motor neurons and neighboring
glial cells in ALS models [39].
The actual contribution of TNFα to the pathophysiology
of ALS remains highly controversial on account of the pleio-
tropic nature of this cytokine and related pathways. Numer-
ous studies have demonstrated altered homeostasis of the
TNFα system in ALS patients and in mouse models of the
disease. Elevated levels of TNFα were reported in the blood
[30, 31, 47] and cerebrospinal fluid (CSF) [48] of ALS
patients. While the high plasma levels, which positively cor-
relate with the illness duration [49], may derive from a large
proportion of TNFα-positive cells in the epidermis and in
some blood vessels and glands of patients, the high CSF
levels may come from the upregulation of TNFα in motor
neurons and reactive microglial/astroglial cells seen in
the spinal cord of individuals affected by sporadic ALS
(Figure 1).
High levels of TNFα were also detected in the spinal
cord of SOD1G93A transgenic mice before symptom onset
[33, 40, 50–52] and in motor neurons and microglia of
symptomatic wobbler mice, another model of motor neuron
disorder [53, 54], suggesting a prominent role of this cytokine
in the development of the disease. Thalidomide and lena-
lidomide, two immune-modulatory drugs that induce the
degradation of TNFα mRNA injected presymptomatically,
lowered TNFα expression in the spinal cord, reduced motor
neuron loss, improved the motor deficit, and increased the
survival of SOD1G93A mice [34]. However, the constitutive
deletion of the gene coding for TNFα in the same mouse
model did not change the lifespan or reduce motor neuron
degeneration [35]. This approach, which completely abol-
ished TNFα expression during development, probably
activated compensatory mechanisms through which the
mutant SOD1 could exert its toxicity. Not only TNFα but
also both its receptors TNFR1 and TNFR2 were markedly
upregulated in the spinal cord of presymptomatic SOD1G93A
[40, 51, 52] and symptomatic wobbler [53] mice. This was
also evident in sporadic ALS patients. In fact, we found sig-
nificant upregulation of TNFR1 and TNFR2 transcripts in
the homogenate of the lumbar spinal cord from ALS patients
compared to nonneurological controls, and this correlated
with an increased immunoreactivity of both receptors in
the reactive astrocytes and dystrophic microglial cells
(Figure 2). Thus, it appears that while TNFα is overproduced
and probably secreted by microglia, astrocytes, and neurons
under stress conditions [55] (Figure 1), its receptors are
upregulated only in the glial cells.
Recently, studying astrocyte-spinal neuron cocultures
from SOD1G93A mice, we noted that upregulation of mTNFα
specifically in motor neurons was detrimental as treatment
with thalidomide or anti-TNFα antibody completely rescued
motor neurons in this experimental paradigm. Interestingly,
the reduction in TNFR2, but not in TNFR1, in either astro-
cytes or neurons as well as treatment with anti-TNFR2
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Figure 1: Immunolocalization of TNFα in the spinal cord of ALS patients. Expression in the cytosol of motor neurons was weak in the control
spinal cord (a). ALS patients showed increased TNFα labeling in the motor neurons (d). Laser scanning confocal micrographs of
immunofluorescence for TNFα (red) and ferritin (microglia, green) (b, e) or GFAP (astrocytes, green) (c, f) show upregulation of TNFα in
the glial cells of ALS patients (e, f, arrows) compared to those of controls (b, c). Magnification: 40x. Spinal cords from sporadic ALS (five
males and three females) and control patients with nondegenerative or nonneurological diseases (three males and three females) were
used. Controls were patients with one of the following: cardiac failure, chronic sepsis, and CNS or non-CNS tumor. The mean age at
death was 60 years (range 52–69) for ALS patients and 64 years (range 55–75) for controls. Duration of illness in ALS cases ranged
between 10 and 60 months. All cases were autopsied within 8 to 15 hours from death. Tissues were fixed in formalin and embedded
in paraffin.
3Mediators of Inflammation
antibody completely abolished the motor neuron death [39].
Since in an astrocyte-free spinal neuronal culture, the soluble
TNFR2 did not rescue the motor neurons, but rather killed
them, we suggested that the detrimental effect of mTNFα
on motor neurons was exerted through a cell contact interac-
tion between the TNFR2 exposed on astrocytes and mTNFα
on motor neuron membranes, through a reverse signaling
mechanism. Thus, we hypothesize that SOD1G93A can render
motor neurons sensitive to astroglial TNFR2, by increasing
the expression of mTNFα in the cell membrane. The detri-
mental role of TNFR2 was confirmed in vivo in SOD1G93A
mice knockout for the receptor, where there was a partial
but significant protection of motor neurons in the lumbar
spinal cord and spared neuromuscular junctions (NMJ) and
conserved morphology of tibialis muscle fibers [39]. How-
ever, these positive effects did not result in any improvement
of motor performance or survival. Motor neurons and their
axons, even if partially preserved, were probably compro-
mised in their function since sciatic nerves expressed lower
levels of acetylated α-tubulin and had increased accumula-
tion of phospho-TDP-43, two indices of axonal dysfunction
that might explain the lack of clinical improvement. In con-
trast, the ablation of TNFR1 significantly increased the loss
of motor neurons and accelerated the disease progression in
SOD1G93A mice [40], suggesting a protective role of TNFα
signaling via TNFR1. The authors demonstrated that this
protective effect was mediated by TNFR1 expressed by astro-
cytes, stimulated by endogenous TNFα to release the glial-
derived neurotrophic factor (GDNF), a potent neurotrophic
factor for motor neurons. These studies clearly indicate that
TNFR1 and TNFR2 expressed by astrocytes can act in oppo-
site directions in governing the survival of motor neurons
under stressful conditions linked to mutant SOD1. There-
fore, with a view to possible therapeutic development, new
strategies are needed to activate TNFR1 and inhibit TNFR2
specifically in astrocytes.
Not so clear, instead, is the role of the upregulation of
both TNFRs in motor neurons of SOD1G93A mice during
the development of the disease [52]. Recently, we demon-
strated by a transcriptomic analysis of laser-dissected motor
neurons from SOD1G93A mice that the synthesis of both
TNFR1 and TNFR2 is significantly increased at the onset
and in the symptomatic stage of the disease, supporting the
idea that intraneuronal cross-talk between TNFR1 and
TNFR2 could play a role in motor neuron death [56]. It
was reported that only the combined deletion of both TNFR1
and TNFR2 receptors prevented motor neuron death after
facial nerve axotomy in adult mice [57]. However, since
TNFR1 mRNA
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Figure 2: Expression of TNFR1 and TNFR2 in the spinal cord of ALS patients. Laser scanning confocal micrographs of immunofluorescence
for TNFR1 (red) and ferritin (microglia, green) or GFAP (astrocytes, green) showed higher expression of TNFR1 in the glial cells of ALS
patients (c, d, arrows) than those of controls (a, b). Magnification: 40x and 60x (inset, d). Immunofluorescence for TNFR2 (red) and
ferritin (microglia, green) or GFAP (astrocytes, green) showed higher levels of TNFR2 in the glial cells of ALS patients (h, i, arrows) than
those of controls (f, g). Magnification: 40x. (e, j) Quantitative RT-PCR analysis of TNFR1 and TNFR2 mRNA levels in the lumbar spinal
cord of ALS patients (n = 12) and controls (n = 6). Data were analyzed by t-test (∗p < 0 05 ALS versus controls).
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TNFR1 and TNFR2 were deleted in neurons and in nonneur-
onal cells, it is hard to define the specific role of each receptor
and cell type in the protective response.
TNFR1 is generally believed to mediate TNFα-induced
cell death signaling, but there is increasing evidence of the
neuroprotective activity of this receptor in neurons, as
reviewed by Probert [58]. For example, Taoufik et al. showed
that neuroprotection induced by erythropoietin and Vascular
endothelial growth factor (VEGF) against oxygen-glucose
deprivation and NMDA excitotoxicity depended signifi-
cantly on the presence of TNFR1 in cortical neurons [59].
In addition, microglia-derived TNFα exerted neuroprotective
effects through TNFR1 on cerebral ischemia [60]. In contrast,
TNFR2, which is commonly considered to promote survival
signaling through direct recruitment of TRAF2 and the
activation of PI3K and NF-κB pathways [41], had toxic
effects on motor neurons in our in vitro and in vivo models
of ALS [39]. Sipe and colleagues also reported a detrimental
role of TNFR2 on neuronal cells [44]. They showed that the
induction of TNFR2 expression on the surface of N1E neuro-
blastoma cells caused cell death through the binding of
mTNFα exposed by adjacent cells, through a cell-to-cell
contact mechanism.
Microglia are considered key players in the neuroinflam-
mation that accompanies the development of ALS. Recent
evidence indicates that TNFα released by activated microglia
is essential in inducing the neurotoxic A1 phenotype in astro-
cytes that lose their trophic function [61] and A1 astroglial
cells were found in autoptic tissues of patients with different
neurodegenerative diseases, including ALS [61]. Importantly,
extracellular SOD1G93A has been reported to activate,
through the CD14-TLR2 pathway, a neurotoxic phenotype
in microglia characterized by the increased release of
proinflammatory cytokines, including TNFα [62]. Further,
activation of the ionotropic purinergic receptor P2X7 in
SOD1G93A microglia leads to the production of significantly
high levels of TNFα, which exert a neurotoxic effect on motor
neuron cultures [63].
LPS activation of NF-κB in microglial cells expressing
mutant TDP-43 is associated with the production of proin-
flammatory cytokines such as TNFα, IL-6, and IFNγ [64].
The release of TNFα by microglia can also generate a self-
sustained autocrine loop via TNFR1 stimulation, inducing a
neuroinflammatory activated phenotype [65], which leads
to a state of chronic neuroinflammation detrimental to
motor neurons. Thus, if TNFR1 in astrocytes is needed for
a protective effect on ALS-injured motor neurons, its pres-
ence in the microglia may be toxic by exacerbating neuroin-
flammation. The specific ablation of TNFR2 in microglia
induced a proinflammatory and more invasive phenotype
of these cells, reducing their homeostatic functions and accel-
erating the onset of the disease in an EAE model of multiple
sclerosis [66].
Oligodendrocytes are another type of a nonneuronal cell
susceptible to TNFα’s action, and their implication in the
pathogenic mechanisms of ALS has been only recently
reported [67]. Oligodendrocytes are severely affected during
the disease, and they degenerate before motor neuron death.
In the attempt to compensate for oligodendrocyte loss,
progenitor cells become highly proliferative but fail to reach
the fully differentiated state [68]. As a result, motor fibers
in the spinal cords of mouse models and ALS patients show
evident signs of demyelination [27, 67]. TNFα interferes with
oligodendrocyte differentiation and causes their death [69],
effects mediated by TNFR1 [70, 71]. In contrast, the activa-
tion of TNFR2 which is mainly expressed in oligodendrocyte
progenitor cells protects these cells from oxidative stress [71].
Therefore, also in oligodendrocytes, a diverging action of
the two TNFα receptors emerges, as in microglia and
astrocytes. However, their relative contributions to the
action of these cells during the development of ALS require
further investigation.
This evidence suggests that the opposite effects of TNFRs
on survival or death of motor neurons depend on the cell
population involved. For example, while the inhibition of
TNFR1 in microglia and oligodendrocytes can be protective
for motor neurons, the response becomes detrimental if the
TNFR1 is inhibited in astrocytes. The opposite is expected
with TNFR2 inhibition.
These data illustrate the difficulty of effectively regulating
the action of TNFα/TNFR signaling on motor neuronal
degeneration. Therefore, information on the downstream
pathways is required to identify specific targets and condi-
tions that allow the balance between beneficial and detrimen-
tal effects of TNFα, to finally obtain neuroprotection.
The difficulty in interpreting the TNFα system’s effects
also lies in the variety of intracellular pathways it can activate,
as widely reviewed [41, 72, 73]. We previously reported that
the high levels of TNFRs in the spinal cord of mutant
SOD1 mice were associated with activation of signaling
involving MKK3-6, MKK4, ASK1, and phosphorylated
p38MAPK (P-pMAPK) in motor neurons and glial cells
[52, 74]. Phospho-p38MAPK accumulation was also found
in the spheroid-like inclusions observed in human ALS
motor neurons [75]. We have recently confirmed that
ASK1 mRNA and immunoreactivity are also elevated in the
spinal cord of ALS patients (Figure 3). This supports the
hypothesis based on the SOD1G93A mouse study of the
involvement of the TNFRs/ASK1/p38MAPK axis in spinal
motor neuron degeneration [52].
To investigate further the interaction between TNFα, its
receptors, and the ASK1/p38MAPK pathway in ALS, we
examined the effect of selective TNFR1 or TNFR2
antagonist-neutralizing antibodies in primary astrocyte-
spinal neuron cocultures expressing SOD1G93A. Unexpect-
edly, the significant increase in phospho-ASK1 (P-ASK1)
immunoreactivity in transgenic large motor neurons was
prevented by inhibition of each of TNFRs separately
(Figure 3). These results suggest that the ASK1/p38MAPK
pathway may, at least in this cellular paradigm, be a con-
vergent target for both the TNFα receptors, but since only
the inhibition of TNFR2 preserved motor neuron from
death [39], the significance of the response to TNFR1
inhibition remains to be clarified. There is ample evidence
that the ASK1/p38MAPK pathway activation is detrimen-
tal to ALS motor neurons. For example, the deletion of
ASK1 reduced motor neuron loss and prolonged the lifespan
of mutant SOD1 mice [76, 77]. In addition, the inhibition
5Mediators of Inflammation
C
TR
A
LS
(a) (b)
(c) (d)
ASK1 mRNA
0
5
10
15
20
25
A
rb
itr
ar
y 
un
its
CTR ALS
⁎
×103
(e)
SMI32 P-ASK1 Merge SMI32 P-ASK1 Merge
un
tr
ea
te
d
A
b 
TN
FR
1
A
b 
TN
FR
2
CTR SOD1G93A
(f)
Untreated Ab TNFR1 Ab TNFR2
0
100
200
300
P-
A
SK
1 
im
m
un
or
ea
ct
iv
ity
(%
 v
er
su
s C
TR
 u
nt
re
at
ed
) ⁎⁎
§§
CTR
SOD1G93A
§§
(g)
Untreated SB239063
0
25
50
75
100
125
150
M
ot
or
 n
eu
ro
n 
su
rv
iv
al
(%
 v
er
su
s C
TR
 u
nt
re
at
ed
)
CTR
SOD1G93A
⁎⁎
(h)
Figure 3: Phosphorylated ASK-1 (P-ASK1) in the spinal cord of ALS patients. The control spinal cord shows a weak cytoplasmic staining for
P-ASK1 in the anterior horn motor neurons (a). ALS patient spinal cords had increased immunoreactivity for P-ASK1 in the cell bodies and
proximal neurites of anterior horn motor neurons (c). P-ASK1 immunostaining was more expressed in the glial cells (astrocytes and
microglia) of ALS patients (d, arrows) than those of controls (b). Magnification: 40x. (e) Quantitative RT-PCR analysis of ASK1 mRNA
levels in the lumbar spinal cord of ALS patients (n = 12) and controls (n = 6). Data were analyzed by t-test (∗p < 0 05 ALS versus controls).
(f) Immunocytochemistry for phosphorylated ASK-1 (P-ASK1, red) in astrocyte-spinal neuron cocultures expressing SOD1G93A and
nontransgenic control (CTR). Large motor neurons expressing SOD1G93A identified by SMI32 labeling (green) and morphological criteria
(maximum diameter and shape) showed greater immunoreactivity for P-ASK1 than those of controls. Three-day treatment with
neutralizing antibodies anti-TNFR1 (AbTNFR1) or anti-TNFR2 (AbTNFR2) reduced immunoreactivity for P-ASK1 in the transgenic
motor neurons. Magnification: 60x; scale bar: 10 μm. The graph (g) shows the quantification of P-ASK1 immunoreactivity. The bar graph
represents mean± SD (% of untreated control) of three independent experiments. Data were analyzed by two-way ANOVA followed by
Tukey’s multiple comparison test (∗∗p < 0 01 compared to untreated CTR; §§p < 0 01 compared to SOD1G93A). (h) Effect of the P-
p38MAPK inhibitor SB239063 on motor neuron viability in astrocyte-spinal cord cocultures expressing SOD1G93A. SB239063 totally
protected transgenic motor neurons in SOD1G93A cocultures after six days in vitro. Data were analyzed by two-way ANOVA followed by
Tukey’s multiple comparison test (∗∗p < 0 01 compared to untreated CTR). All experiments with cell cultures were done as previously
described [45].
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of p38MAPK with the selective antagonist SB239063
completely prevented motor neuron death in SOD1G93A
cocultures (Figure 3). This agrees with a recent report that
CIIA mitigated SOD1G93A-induced cytotoxicity by inhibit-
ing the activation of ASK1/p38MAPK signaling [78]. In
addition, previous studies showed significant protection
of motor neurons and proximal axons in SOD1G93A mice
after administration of the p38MAPK inhibitor semapimod
[79], although this effect was not accompanied by an increase
in survival.
These data suggest the importance of the TNFR2/ASK1/
p38MAPK pathway in the mechanisms of motor neuron
degeneration and point out the growing evidence of a disso-
ciation between the protection of motor neurons and the lack
of an effect on mouse survival. This is probably because var-
ious cellular components are involved in ALS pathology, like
muscles and the immune system, that can react differently to
therapeutic agents or genetic manipulation.
3. TNFα and the Immune System in ALS
Evidence is accumulating that the immune system, both
innate and adaptive, is critical in the pathology of ALS
[6, 23, 26, 28]. In the CNS microglia and macrophages, the
local components of the innate immune response become
activated in the affected tissues in response to priming events,
for example, misfolded and aggregated proteins, mitochon-
drial dysfunction, or impaired axonal transport, triggering
neuroinflammation. This may lead to a state of chronic acti-
vation of the innate and adaptive immune system as indi-
cated by the infiltration of macrophages, dendritic cells, and
T lymphocytes (CD4+ and CD8+) in the central [6, 80] and
peripheral nervous system [81] of SOD1G93A mice at differ-
ent stages of the disease, as well as in postmortem tissues
from patients [23, 26].
Although initially neuroinflammation was considered
detrimental in ALS, this idea was challenged by the demon-
stration of a dual role of immunity with protective and toxic
phases during the disease progression: an early M2/Th2
protective phase characterized by stable disease and a late
M1/Th1 phase characterized by rapid disease progression
[82, 83]. During the early stable phase, the immune system
is protective with glia and T cells, especially M2 microglia/
macrophages and T helper 2 cells (Th2)/regulatory T cells
(Treg), providing anti-inflammatory factors that sustain
motor neuron viability. This phase is characterized by
enhanced IL-10 and IL-4 expression in the spinal cord and
accumulation of FoxP3, a marker of suppressive Treg cells
in the spinal cord, lymph nodes, and blood of mutant
SOD1 mice, followed by an overall decrease as the disease
progresses [84]. Interestingly, ALS patients have low levels
of circulating Tregs [24], with an inverse correlation between
the rate of disease progression and the percentages of
circulating Treg and FoxP3 [85]. Therefore, low Treg and
FoxP3 mRNA levels were proposed as accurate biomarkers
predicting rapid disease progression [86]. In addition, pas-
sive transfer of Tregs from donor ALS mice during the
early slow phase or by ex vivo cell expansion extended
the early phase and prolonged survival of recipient
SOD1G93A mice [87, 88], demonstrating the neuroprotective
properties of these cells. The enhanced neuroprotection by
Treg cells was attributed to the release of anti-inflammatory
cytokines with subsequent maintenance of M2 microglia
and suppression of effector T cells (Teffs). Thus, increasing
the Tregs in patients at the early stages of the pathological
process might be a promising therapeutic approach to
hamper the disease progression [86].
Among the factors that exert strong activity on Tregs,
TNFα plays a major role, although with divergent effects.
In fact, TNFα can either promote Treg proliferation and
expansion or limit the suppressive capacity [89]. There-
fore, depending on which effect prevails, TNFα may exert
either protective (anti-inflammatory) or pathogenic (proin-
flammatory) activity. TNFR2, but not TNFR1, is expressed
by human and mouse CD4+/FoxP3 Treg, in the steady and
activated state [90], and it has been suggested that the
coexpression of CD25 with TNFR2 could mark the cells
with the most suppressive capacity [91].
In addition to the ability to induce proliferation of Tregs,
TNFα may also control their suppressive function. TNFα
strongly downregulated FoxP3 expression in human Treg
cells [92] and inhibited its phosphorylation [93]. Therefore,
TNFα and its receptors, particularly TNFR2, might poten-
tially be able to tip the balance between pathogenic Teff cells
and protective Treg cells in both directions, depending on
synergy with other inflammatory factors. For example,
IL-6 which is overexpressed in ALS at the later phases also
inhibits the generation of FoxP3+ Treg cells induced by
TGF-beta [94] and may act in synergy with TNFα to
reduce Treg function. Therefore, considering the high
expression of FoxP3 in mutant SOD1 mice at the early
stage of the disease [88], it is reasonable to assume that
an initial TNFα-TNFR2 interaction may be critical for
the early neuroprotective activity, while in the late phase,
the increased levels of both TNFα and IL6 may synergize
to suppress the protective Treg. However, when we examined
the levels of FoxP3 in the spinal cord of SOD1G93A mice lack-
ing the TNFR2 receptors, we did not find difference from
SOD1G93A/TNFR2+/+ mice. Therefore, Treg modulation
may not be a primary mechanism in the motor neuron
protection derived from TNFR2 inhibition.
On the other hand, we confirmed that Treg levels in the
spinal cords of SOD1G93A mice at an advanced symptomatic
stage were significantly lower than those in the spinal cords
of nontransgenic littermates, in line with the hypothesis of
a reduction in these cells during the late M1 phase of disease
progression. TNFR2 deficiency in mice has been reported to
lower the overall cytokine production and proliferation of
CD8+ T cells [95]. Therefore, we cannot exclude that the
general depletion of TNFR2 could have reduced the later
detrimental proinflammatory effect of the M1/T1 phase in
both the central and peripheral compartments, preventing
the massive loss of motor neurons and neuromuscular
junction in SOD1G93A mice at the symptomatic stage. It
remains to be explained why the protection of the neuro-
muscular system in SOD1G93A/TNFR2-knockout mice was
not associated with an improvement in the disease course.
Conceivably, some overall proinflammatory activity of
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TNFα, through TNFR1, or other proinflammatory cyto-
kines like INFγ and IL-6 may have a negative impact on
the muscle wasting and general metabolic changes seen
in these mice during symptom progression, masking the
benefit resulting from the protection of the motor neurons
and NMJs.
4. TNFα and Muscle Wasting in ALS
TNFα is a cell signaling protein responsible for several
metabolic derangements leading to muscle wasting [96]. It
promotes a wasteful metabolic process in muscles, leading
to increased protein degradation and consequent loss of skel-
etal muscle mass. This occurs through a pathway in which
reactive oxygen species (ROS) and NF-κB are the early medi-
ators of a cascade leading to protein degradation through
activation of the ubiquitin proteasome pathway (UPP). The
intracellular ROS induced by the activity of TNFα leads to
activation of IKKb, making NF-κB available for translocation
to the nucleus where it activates the expression of genes that
regulate the UPP. In doing this, TNFα not only promotes the
loss of proteins but also becomes responsible for transcrip-
tion regulation, cell cycle progression, and antigen presenta-
tion in the muscles [97]. This process mediated by TNFR1,
not TNFR2, is involved in muscle protein degradation and
wasting [98].
The progressive wasting of skeletal muscle is the main
cause of the loss of strength, motor disability, paralysis, and
death in ALS. Although the dismantlement of neuromuscu-
lar junctions is considered the primary cause of muscle
atrophy, ALS patients and mouse models all show clear
muscle dysmetabolism/hypermetabolism in relation to dis-
ease progression [99]. Proteomic analysis of gastrocnemius
muscle from SOD1G93A mice with clear signs of motor
impairment reported an accumulation of ROS together with
an increase in NF-κB and impaired mitochondrial respira-
tory function. Unlike in the spinal cord, no accumulation of
mutant SOD1 was found in the skeletal muscle of SOD1G93A
mice during the disease progression [100]. This suggests that
the induction of NF-κB in the muscle of mutant ALS mice
may activate the machinery for misfolded protein degrada-
tion, that is, UPP and autophagy, in clear contrast with
what happens in the spinal cord [101]. It is still not
known whether the NF-κB activation in ALS mouse muscle
is mediated by TNFα. However, an active inflammatory
response, with elevated levels of TNFα, was recently reported
in the hindlimb muscles of SOD1G93A rats [102], suggest-
ing that TNFα-mediated inflammation might contribute to
the muscle wasting in SOD1 mice and perhaps in ALS
patients too.
TNFα also plays an important role in the metabolic alter-
ations like altered lipid and carbohydrate metabolism and
insulin resistance that are typical of cachexia syndrome
[96]. Cachexia is a clinical condition much akin to ALS.
The syndrome is characterized by weight loss due to loss of
both muscle and adipose tissues but with disproportionate
muscular wasting in patients with cancer or other chronic
systemic disorders like inflammatory diseases (sepsis,
rheumatoid arthritis, and HIV) or cardiac, renal, and respira-
tory insufficiency [103].
Patients with ALS are generally lean and lose body mass,
muscle mass, and fat as the disease progresses [99]. An asso-
ciation of diabetes and insulin resistance with ALS has been
suggested in several studies, although there are controversial
opinions on whether this association is protective or detri-
mental to the disease development and progression [5]. Insu-
lin resistance has been considered an important mechanism
for the muscle wasting in cachexia as it increases proteolysis
by increasing the expression of UPP components [104],
and TNFα is responsible for this [96]. Therefore, consider-
ing the high TNFα levels found in biological fluids of ALS
patients [30, 31, 48], we cannot exclude a potential role of
this cytokine in the metabolic derangements associated
with the disease.
5. TNFα and Glutamate-Mediated Excitotoxicity
Another mechanism through which TNFα can induce or
otherwise affect the motor neuron degeneration in ALS
involves its action on excitotoxicity. Excitotoxicity is the
result of excessive activation of glutamate receptors which
may be due to failure in neurotransmitter clearance from
the synaptic cleft or increased postsynaptic sensitivity to
glutamate. The first evidence of an involvement of excitotoxi-
city in ALS was the markedly high glutamate levels in the
cerebrospinal fluid of ALS patients [105]. This was later
attributed to altered glutamate clearance from the synap-
tic cleft due to the reduced expression and function of theNa+-
dependent glutamate transporter EAAT2 (GLT-1 in rodents)
in ALS patients [106] and mouse models [107, 108]. This
transporter, which is responsible for removing up to 94% of
glutamate from the synaptic cleft, is present on the astrocytic
processes that envelop the synapse [109].
Overactivation of amino-3-hydroxyl-5-methyl-4-isoxa-
zole-propionate (AMPA) receptors is considered the main
cause of excitotoxicity for motor neurons. Spinal motor neu-
rons possess several Ca2+-permeable AMPA receptors under
basal conditions, and this high density may increase suscep-
tibility to degeneration [110–112]. AMPA receptor calcium
permeability is largely determined by the GluR2 subunit
which is posttranscriptionally edited, changing a codon
encoding glutamine to one encoding arginine (Gln/Arg) in
the second transmembrane domain, making the receptor
complex impermeable to calcium. Reduced GluR2 subunits
have been reported in spinal motor neurons of ALS patients
[110] and SOD1G93A mutant mice [113], making them highly
permeable to calcium and more susceptible to excitotoxic
insults. In keeping with this, the overexpression or deficit
of GluR2 subunits in SOD1G93A mice improved or acceler-
ated the disease progression, respectively [111, 114], while
different AMPA receptor antagonists slowed the disease
progression and prolonged the survival of SOD1 mutant
mice [113, 115]. Unfortunately, in patients, the noncom-
petitive AMPA antagonist talampanel failed to improve
the disease course [116].
Thus, multifaceted evidence suggests that increased glu-
tamatergic neurotransmission may contribute to the motor
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neuron neurodegeneration in ALS even if inhibitors of the
excitotoxicity, except for riluzole, have failed in clinical trials
[117]. TNFα is the first endogenous mediator known to
influence the excitotoxicity and the extracellular levels of
glutamate by both enhancing its release and reducing its
reuptake [118]. The first evidence comes from studies in
human neuronal cultures showing that subtoxic doses of
TNFα and AMPA became neurotoxic when combined
[119]. Hermann and colleagues then demonstrated that
nanoinjections of nontoxic doses of TNFα and kainate
combined in rat spinal cord led to neuronal cell death which
was reversed by an AMPA receptor antagonist [120].
TNFα is also a critical component of the regulatory
system controlling synaptic plasticity [121], synaptic
strength, and excitability by modifying AMPA receptor
trafficking. This occurs through a deficiency of GluR2 with
a consequent increase in Ca2+ permeability [122]. In line with
this, TNFα can potentiate AMPA receptor-mediated excito-
toxicity on lumbar spinal motor neurons by inducing rapid
membrane reassortment with a heavy presence of Ca2+-per-
meable AMPA receptors [123]. TNFα was also reported to
downregulate astrocytic EAAT2/GLT-1 expression, and this
effect was mediated through the NF-κB binding to the
EAAT2 promoter [124, 125]. Another mechanism through
which TNFα may promote excitotoxicity has been demon-
strated in cultured astrocytes through the binding of TNFα
to TNFR1, which raises intracellular calcium, followed by
glutamate exocytosis [126]. In mouse primary microglia
too, TNFα can induce excitotoxicity in an autocrine manner
through the TNFR1 pathway, by promoting microglial
release of glutamate [127].
Finally, besides increasing the surface expression of gluta-
mate receptors, TNFα also induces endocytosis of GABA-A
receptors, reducing their inhibitory action [128]. Thus, the
exacerbation of excitotoxicity mediated by TNFα can occur
at different levels: (i) by increasing the expression of
calcium-permeable AMPA receptors in motor neurons, (ii)
by reducing glutamate reuptake by astrocytes, and (iii) by
increasing glutamate release from microglia through the
TNFR1 pathway. On the basis of these data, it would be rea-
sonable to propose the inhibition of TNFα/TNFR1 signaling
as a neuroprotective therapeutic approach. However, as dis-
cussed earlier, TNFR1 activation in astrocytes is vital for
the release of GDNF and the protection of motor neurons.
Therefore, the overall manipulation of TNFR1 receptors in
the CNS may have opposite effects on motor neuron survival,
making this approach impracticable for pharmacological
therapy in ALS. Only the targeted therapeutic approaches
using gene therapy or engineered molecules to selectively
interfere with the expression and activity of this receptor
in a cell-specific manner might effectively improve the
disease progression.
6. Anti-TNFα Therapy in ALS
Although there is no doubt that TNFα plays a role in ALS, as
reviewed here and elsewhere, different anti-inflammatory
treatments intended to lower its levels have achieved only
partial improvement, no effect, or even exacerbation of the
symptoms in animal models and patients. For example,
minocycline, which reduces the synthesis of TNFα and other
inflammatory mediators, delayed the disease progression
in mutant ALS mice [129] but had harmful effects on
patients in a phase III randomized clinical trial [130]. Sim-
ilar results were obtained with thalidomide, a more specific
TNFα synthesis inhibitor, which partially relieved the motor
deficit and prolonged the survival of SOD1G93A mice [34] but
caused adverse effects and did not effectively affect the
disease progression of ALS patients in a phase II clinical
trial [36].
There are several possible reasons for the different
responses in animal models and patients. A major issue is
that in the mouse models treatment is often given before
the symptom onset; on the contrary, in patients, the disease
is usually already advanced by the time of diagnosis and
treatment, so the motor neurons are already markedly
compromised. In fact, when minocycline was given to
SOD1 mutant mice after the disease onset, it did not affect
survival and exacerbated the inflammatory milieu around
motor neurons [131].
It is likely—as evidenced from this review—that TNFα/
TNFR signaling has many different roles at the different
stages of disease and only targeting it in the initial phase
may prevent the massive loss of motor neurons and rapid
progression of the pathology. Therefore, it becomes essential
to identify early diagnostic markers in patients to allow
prompt pharmacological intervention with anti-TNFα thera-
pies. Although thalidomide and lenalidomide completely
rescued the spinal motor neuron degeneration in SOD1
mutant mice, the gains in motor performance and in lifespan
were only transient and modest, suggesting that other parts
of the neuromuscular system were not preserved by anti-
TNFα therapy. This is probably explained by the pleiotropic
action of TNFα and the different contributions of its recep-
tors in a multicellular disease involving motor neurons,
astrocytes, microglia, infiltrated immune cells, and muscles,
as discussed earlier. What is needed now is novel, highly
specific, and selective anti-TNFα therapeutic approaches to
ensure the efficacy and safety of treatments in ALS.
A wide range of different biologic molecules and immu-
nomodulatory drugs have been developed to inhibit the
action of TNFα and/or interfere with their receptor activity
as a therapeutic strategy in inflammatory peripheral disease
and autoimmune disorders [41, 45]. They include FDA-
approved biologics that bind to both mTNFα and sTNFα,
preventing the binding and activation of TNFα receptors.
However, the pleiotropic nature of TNFα and the nonspecific
activity of these molecules lead to serious side effects such as
lymphoma, congestive heart failure, demyelinating disease,
and infections [132].
Despite these drawbacks and the poor penetration of the
blood-brain barrier by these agents, clinical trials with
etanercept, a genetically engineered Fc fusion protein gener-
ated from the extracellular domain of human TNFR2 which
blocks both sTNF and mTNF, have been conducted in
patients with Alzheimer disease (AD), with significant
cognitive and behavioral improvements [133, 134]. On the
contrary, treatment of multiple sclerosis (MS) patients with
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lenercept, a dimeric TNFR1 extracellular domain fused to a
human IgG1, was stopped during a phase II randomized
study, due to an increase in the frequency, duration, and
severity of MS attack [135]. The failure was probably caused
by the nonspecific inhibition of both sTNFα and mTNFα
which acting through TNFR1 and TNFR2, respectively, can
mediate nerve demyelination or remyelination through dif-
ferent pathways, as reviewed by McCoy and Tansey [41].
To date, no clinical trials have been conducted in ALS
using these anti-TNFα biologics. However, case reports have
been published showing patients developing ALS after long
treatments with anti-TNFαmolecules. Dziadzio and collabo-
rators described a patient with rheumatoid arthritis who was
diagnosed with ALS after receiving infliximab for five years
[136]. Subsequently, several other ALS cases treated with
TNFα blockers (adalimumab, etanercept, infliximab, and
others) for rheumatoid arthritis and ankylosing spondylitis
were reported [137–139]. Although a direct causal relation-
ship between ALS development and TNFα blockers has not
been established [140], it cannot be excluded that interfering
with the TNFα system for a long time can worsen or even
trigger motor neuron degeneration, given the potential
neuroprotective effect of TNFα that we have described in this
review. All these evidences strongly suggest that general
inhibition of TNFα cannot achieve any notable benefit
because it can interfere with different mechanisms with
opposite activity at the same time.
The recent demonstration of the protective function
shown by astroglial TNFR1 through the production of
GDNF [40] in an ALS mouse model and the neurotoxic
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Figure 4: Potential mechanisms by which TNFα and its receptors TNFR1 and TNFR2 contribute to the neuropathology in ALS. Both
neuroprotective and neurotoxic functions are proposed for TNFR1 and TNFR2, depending on the cell type involved.
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activity of TNFR2 carried by astrocytes and neurons [39]
mediated by the ASK1/p38MAPK pathway suggests that a
future targeted therapeutic strategy should selectively poten-
tiate the TNFR1 response and antagonize TNFR2 or its
downstream signaling, in a cell-specific manner.
7. Summary and Conclusions
Neuroinflammation and the immune response, both innate
and adaptive, are considered to actively contribute to the ini-
tiation and propagation of ALS, a pathology that involves dif-
ferent cell types in the neuromuscular, glial, and peripheral
immune systems. TNFα is the major cytokine instrumental
in governing these mechanisms (Figure 4). However, its
action can influence the pathophysiology either positively
or negatively depending on the type of receptor and cell
involved throughout all stages of the disease (Table 1). For
example, while through its action on TNFR2, TNFα may
activate Treg cells that regulate the initial neuroprotective
M2/T2 phase of the disease by releasing anti-inflammatory
cytokines; the active interaction between this receptor local-
ized on the surface of astrocytes and the mTNFα on motor
neurons may trigger a cascade leading to motor neuron
death. Thus, TNFR2 inhibition should be driven specifically
to the astrocytes to prevent motor neuron degeneration. At
the same time, strategies aimed at increasing the expression
and/or activity of TNFR2 in the Tregs and olygodendrocytes
may promote an immunomodulatory function, prolonging
the M2 phase and promoting remyelination. The role of
TNFR1 in regulating the disease progression appears far
more complicated. While the activation of TNFR1 on
astrocytes induces GDNF release protecting motor neurons,
its activation also provokes a reduction in the glutamate
transporter GLT1 causing an increase in extracellular gluta-
mate with potential excitotoxic effects. Excitotoxicity may
also result from the activation of TNFR1 on microglia due
to excessive glutamate release from these cells. Finally,
increased TNFR1 signaling activity in the CNS could lead
to the degeneration of oligodendrocytes with consequent
axonal demyelination, while its activation in muscle may
lead to excessive protein degradation, hence skeletal muscle
wasting and atrophy.
These findings seem to indicate an overall detrimental
effect of TNFR1 on ALS pathology. However, the fact that
mutant SOD1 mice with a constitutive depletion of TNFR1
have a shorter lifespan suggests that the activity of this
receptor in the various cell types may be balanced during
ALS course, possibly depending on the levels of TNFα
and/or on the activity of the antithetic TNFR2 receptors
in the same cells.
Given the rapid development of new curative strategies
based on cell-specific targeting, for example, through gene
therapy or engineered molecules, we can envisage the possi-
bility of more selective anti-TNFα agents that may regulate
TNFR expression and downstream signaling in specific cell
populations. The role of the TNFα/TNFR pathway in ALS
calls for further investigations.
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Table 1: Effects of the activation of TNFRs on different cell types.
Cell types Activation of TNFR1 Activation of TNFR2
Motor neurons Cell death [39]
Astrocytes Release of GDNF [40], increase in intracellular Ca2+, and release
of glutamate [123]
Death of cocultured motor neurons [39]
Microglia Activation of proinflammatory phenotype [63] and release
of glutamate [124]
Induction of anti-inflammatory phenotype [64]
Oligodendrocytes Cell death and reduced differentiation [68, 69] Protection from oxidative stress [71]
CD8+ T cells Increased cytokine production and proliferation [93]
Treg cells Proliferation and suppressing function control [89]
Muscle cells Protein degradation and muscle wasting [96]
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